Le Lézard
Classified in: Health
Subject: PSF

BRW Safety & Supply Is Excited to Stock Must-Have CPR Microkey


SANTA ANA, Calif., May 18, 2018 /PRNewswire/ -- According to the CPR Headquarters over 350,000 out-of-hospital cardiac arrests occur in the United States per year, out of which 70% happen inside homes. 90 percent of people who suffer cardiac arrest die prior to reaching a hospital or medical care facility.

It turns out that cardiac arrests are not uncommon medical emergencies in the US. When it occurs, whether at home or in the workplace only about 20 percent of Americans are equipped to perform CPR during a medical emergency situation, according to an AHA Study.

The survival chances of a victim if a bystander does not perform CPR will decrease 7% in every single minute of delay.

BRW Safety & Supply has spent over 40 years offering products that help maintain a safe work environment and beyond.  "When we looked at the scary stats of Americans who could have been saved by an effective CPR, we decided to stock the MDI CPR Microkey to help anyone anywhere save lives in case of emergencies. This is part of our safety mission that we have been committed to for over 40 years," said Christopher Gallagher, the CEO of BRW Safety & Supply.

It is this mission that has led the company to partner with Medical Devices Inc to add the MDI CPR Microshield MicroKey Rescue Breather to its array of quality safety products.

BRW's CPR Microkey can help bystanders, coworkers and family members easily perform CPR on victim to save lives.

BRW Safety & Supply hopes that every workplace and home first aid kit is equipped with the CPR Microkey to ensure heart attack victims receives the required oxygen concentration of 20 to 21 percent to stay alive.

Media Contact:

Michael Pomposello
855-258-3765
[email protected]

SOURCE BRW Safety & Supply


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: